

#### Ruxandra Draghia-Akli MD PhD


Director Health DG Research & Innovation Towards a new PPP on biomedical Research and Innovation under Horizon 2020

# HORIZON 2020

esearch and



#### **R&D** investment: fuel for the economy





## What is Horizon 2020

- Commission proposal for a 80 billion euro research and innovation funding programme (2014-2020)
- A core part of Europe 2020, Innovation Union & European Research Area:
  - **Responding to the economic crisis** to invest in future jobs and growth
  - Addressing people's concerns about their livelihoods, safety and environment
  - Strengthening the EU's global position in research, innovation and technology





# **Three Priorities:**

Excellent science (€24.5 billion)
Industrial leadership(€17.9 billion)
Societal challenges (€31.7 billion)

Research and Innovation



# **Priority 3. Societal Challenges**

Why:

- Concerns of citizens and society/EU policy objectives (climate, environment, energy, transport etc) cannot be achieved without innovation
- Breakthrough solutions come from multidisciplinary collaborations, including social sciences & humanities
- Promising solutions need to be tested, demonstrated and scaled up





#### Proposed Funding (million euro, 2014-2020)

Health, demographic change and wellbeing	8 033
Food security, sustainable agriculture, marine and maritime research & the bioeconomy	4 152
Secure, clean and efficient energy*	5 782
Smart, green and integrated transport	6 802
Climate action, resource efficiency and raw materials	3 160
Inclusive, innovative and secure societies	3 819

\*Additional €1 788m for nuclear safety and security from the Euratom Treaty activities (2014-2018). Does not include ITER.

Research and Innovation



#### Simplification

- Single set of simpler and more coherent participation rules
- New balance between trust and control
- Moving from several **funding rates** for different beneficiaries and activities to just two
- Replacing the four methods to calculate overhead or «indirect costs» with a single flat rate
- Major simplification under the forthcoming financial regulation
- Successful applicants to get working more quickly: reduction of average time to grant





## **Next Steps**

- **Ongoing:** Parliament and Council negotiations on the basis of the Commission proposals
- **Ongoing:** Parliament and Council negotiations on EU budget 2014-2020 (including overall budget for Horizon 2020)
- **Ongoing:** Final calls under 7th Framework Programme for research to bridge gap towards Horizon 2020
- Mid 2013: Adoption of legislative acts by Parliament and Council on Horizon 2020
- 1/1/2014: Horizon 2020 starts, launch of first calls





# **Horizon 2020 and Partnering**

#### Public-private partnerships (PPPs):

- Through Joint Technology Initiatives or other formal structures (Art. 187)
- Through contractual agreements, which provide inputs for work programmes
- Only when criteria met, <u>e.g. clear commitments</u> <u>from private partners</u>

**Also: public-public partnerships** (e.g. ERA-Nets, Joint Programming Initiatives)





#### Moving Forward with a PPP in Innovative Health Research

#### **Criteria to be fulfilled**

- (a) Added value of action at Union level;
- (b) Scale of impact on industrial competitiveness, sustainable growth and socio-economic issues;
- (c) Long-term commitment from all partners based on a shared vision and clearly defined objectives;
- (d) Scale of the resources involved and the ability to leverage additional investments in research and innovation;
- (e) Clear definition of roles for each of the partners and agreed key performance indicators over the period chosen.





## **Key Processes / Timelines**

- For a new PPP implemented under Article 187 of the TFEU a legislative proposal from the Commission will be required
- Impact assessment exercise ongoing
- Closely following the consultations about the rules for participation in Council and Parliament
- Preparation of the model financial regulation for "light union bodies"
- Preparations for making a legislative proposal next year, after adoption of Horizon 2020





## Status of Preparations for Impact Assessment for Life Science PPP under Horizon 2020

- Online public consultation closed 4 October, 134 replies; online consultation of IMI participants closed 4 October; 239 replies, representing 42.9% of unique participants
- Targeted consultation of stakeholders
- Appointment of expert group to support Commission in preparation of impact assessment: F. Gvillo (USA – chair), N. Safrany (FR – rapporteur), M. Aguirre (ES), M. Szumowski (PL), J. Knowles (UK)



#### **Targeted Stakeholder Consultations through Meetings/Conferences (1)**

- CEOs of EFPIA companies with Commissioner Geoghegan-Quinn on 26 June
- Global heads of research of EFPIA companies, as well as regulators, academic investigators and representatives of WHO on 3 September
- *Representatives of SMEs on 19 September*
- European coordination committee of the radiological, electromedical and health care IT industry (COCIR) on 19 September 2012





#### Targeted Stakeholder Consultations through Meetings/Conferences (2)

- Patient representatives through the EFPIA Patient Think Tank on 28 September 2012
- Today's IMI SRG meeting and IMI conference in the context of the Cyprus presidency event InnovaHealth conference (11 through 13 October)
- Regulators European Medicines Agency (EMA) and the Food and Drug Administration of the USA (FDA) on 7 November





# Thank you for your attention!

Find out more:

www.ec.europa.eu/research/horizon2020

Research and Innovation